CANNABIDIOL AS AN ADD-ON THERAPY IN TUBEROUS SCLEROSIS COMPLEX

WHAT
Safety and efficacy of cannabidiol (CBD)

WHO
People aged 1 year to 65 years with Tuberous Sclerosis Complex (TSC)

WHERE
Epilepsy Centers throughout the United States

HOW
16 weeks of treatment with either CBD or a placebo
Followed by the opportunity for all participants to receive CBD for an initial period of 1 year

IMPORTANT CONSIDERATIONS
You must be willing for your primary care doctor and other responsible authorities to be notified of your participation in this study, if it is required by law in your state. Your liver function will be monitored throughout the study. If you are pregnant, taking an mTOR inhibitor, or have liver impairment, you are not eligible to participate due to increased risk with CBD.

For more information, visit
https://www.epilepsy.com/greenwich